HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marek Z Wojtukiewicz Selected Research

Factor X (Stuart Factor)

5/2019Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue.
5/2014Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer.
4/2012Protein Z/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue.
4/2012Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells.
1/2012[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marek Z Wojtukiewicz Research Topics

Disease

40Neoplasms (Cancer)
10/2021 - 10/2002
13Breast Neoplasms (Breast Cancer)
10/2021 - 10/2002
8Neoplasm Metastasis (Metastasis)
03/2019 - 02/2004
5Thrombosis (Thrombus)
05/2020 - 07/2004
5Colonic Neoplasms (Colon Cancer)
04/2012 - 07/2003
4Colorectal Neoplasms (Colorectal Cancer)
10/2020 - 10/2002
4Pain (Aches)
03/2019 - 01/2012
3Febrile Neutropenia
04/2019 - 02/2005
3Head and Neck Neoplasms (Head and Neck Cancer)
03/2019 - 01/2017
3Hemorrhage
01/2017 - 12/2003
3Renal Cell Carcinoma (Grawitz Tumor)
10/2016 - 10/2002
3Neointima
01/2005 - 07/2003
2Glioma (Gliomas)
01/2021 - 01/2021
2Carcinoma (Carcinomatosis)
09/2019 - 06/2003
2Endometrial Neoplasms (Endometrial Cancer)
05/2019 - 07/2003
2Carcinogenesis
01/2019 - 10/2002
2Pulmonary Embolism
01/2017 - 01/2012
2Anemia
11/2015 - 04/2009
2Stomach Neoplasms (Stomach Cancer)
05/2014 - 06/2003
2Disease Progression
10/2012 - 01/2011
2Thrombocytosis (Thrombocythemia)
10/2007 - 02/2004
1Lung Neoplasms (Lung Cancer)
10/2021
1Melanoma (Melanoma, Malignant)
10/2021
1Neoplastic Processes
01/2021
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/2019
1Drug-Related Side Effects and Adverse Reactions
04/2019
1Non-Hodgkin Lymphoma (Lymphosarcoma)
04/2019
1Cancer Pain
03/2019
1Dyspnea (Shortness of Breath)
02/2018
1Edema (Dropsy)
02/2018
1Cachexia
02/2018

Drug/Important Bio-Agent (IBA)

15Proteins (Proteins, Gene)FDA Link
10/2021 - 06/2003
12Hemostatics (Antihemorrhagics)IBA
01/2021 - 06/2003
11Thromboplastin (Tissue Factor)IBA
05/2016 - 10/2002
7FibrinIBA
01/2021 - 06/2003
7lipoprotein-associated coagulation inhibitor (TFPI)IBA
01/2021 - 10/2002
6Prothrombin (Factor II)IBA
01/2021 - 06/2003
6ThrombinFDA Link
01/2021 - 06/2003
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 06/2003
6AnticoagulantsIBA
05/2020 - 02/2004
6plasma protein Z (protein Z)IBA
05/2014 - 12/2003
5Protein CIBA
01/2021 - 06/2003
5Fibrinogen (Factor I)FDA Link
01/2021 - 06/2003
5Factor X (Stuart Factor)IBA
05/2019 - 01/2012
5Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2005 - 06/2003
4Plasminogen Activators (Plasminogen Activator)IBA
01/2021 - 06/2003
4Protein SIBA
01/2021 - 06/2003
4Blood Coagulation Factors (Coagulation Factor)IBA
05/2019 - 02/2005
4Messenger RNA (mRNA)IBA
05/2014 - 10/2007
4Protease Inhibitors (Protease Inhibitor)IBA
05/2014 - 07/2010
3tissue-factor-pathway inhibitor 2 (PP5)IBA
01/2021 - 07/2003
3Biological ProductsIBA
01/2019 - 04/2006
3Pharmaceutical PreparationsIBA
02/2018 - 08/2006
3Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
01/2017 - 02/2004
3Proteinase-Activated ReceptorsIBA
07/2016 - 12/2015
3PolyestersIBA
01/2005 - 07/2003
3Tissue Plasminogen Activator (Alteplase)FDA Link
07/2003 - 06/2003
2Plasminogen Activator Inhibitor 1IBA
01/2021 - 12/2004
2AntigensIBA
01/2021 - 06/2003
2ThrombomodulinIBA
01/2021 - 03/2010
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
04/2019 - 05/2016
2pegfilgrastim (Neulasta)FDA Link
04/2019 - 02/2005
2Analgesics (Analgesic Drugs)IBA
03/2019 - 10/2015
2Peptide Hydrolases (Proteases)FDA Link
01/2019 - 02/2004
2Trastuzumab (Herceptin)FDA Link
01/2018 - 01/2011
2Doxorubicin (Adriamycin)FDA LinkGeneric
10/2016 - 05/2016
2EnzymesIBA
06/2016 - 08/2015
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
05/2016 - 10/2012
2Docetaxel (Taxotere)FDA Link
05/2016 - 02/2005
2Carcinoembryonic AntigenIBA
08/2011 - 10/2002
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
10/2007 - 02/2004
2Thrombopoietin (c-mpl Ligand)IBA
10/2007 - 02/2004
2Urokinase Plasminogen Activator ReceptorsIBA
01/2005 - 06/2003
2von Willebrand FactorIBA
12/2003 - 06/2003
2Plasminogen InactivatorsIBA
07/2003 - 06/2003
2PlasminogenIBA
07/2003 - 06/2003
1Blocking AntibodiesIBA
10/2021
1Immune Checkpoint ProteinsIBA
10/2021
1Immune Checkpoint InhibitorsIBA
01/2021
1AntithrombinsIBA
10/2020
1Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
05/2020
1AntibodiesIBA
05/2019
1RadiumIBA
03/2019
1Radioisotopes (Radionuclides)IBA
03/2019
1Diphosphonates (Bisphosphonates)IBA
03/2019
1StrontiumIBA
03/2019
1Endothelial Protein C ReceptorIBA
01/2019
1PAR-1 ReceptorIBA
01/2019
1MegestrolIBA
02/2018
1ErbB Receptors (EGF Receptor)IBA
01/2018

Therapy/Procedure

11Therapeutics
01/2021 - 02/2004
8Drug Therapy (Chemotherapy)
10/2020 - 02/2005
6Radiotherapy
09/2019 - 10/2015
5Chemoradiotherapy
03/2019 - 10/2015
2Immunotherapy
10/2021 - 01/2021
2Prosthesis Implantation
12/2004 - 07/2003
1Brachytherapy
03/2019
1Perioperative Period
02/2018
1Hospice Care (Care, Bereavement)
02/2018
1Neoadjuvant Therapy
01/2018